Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer

  • Authors:
    • Mohammad Hashemi
    • Shadi Amininia
    • Mahboubeh Ebrahimi
    • Nasser Simforoosh
    • Abbas Basiri
    • Seyed Amir Mohsen Ziaee
    • Behzad Narouie
    • Mehdi Sotoudeh
    • Mohammad Javad Mollakouchekian
    • Esmaeil Rezghi Maleki
    • Hamideh Hanafi‑Bojd
    • Maryam Rezaei
    • Gholamreza Bahari
    • Mohsen Taheri
    • Saeid Ghavami
  • View Affiliations

  • Published online on: February 14, 2017     https://doi.org/10.3892/ol.2017.5739
  • Pages: 2483-2489
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor protein 53 (TP53), a tumor suppressor gene, is a vital cellular cancer suppressor in multicellular organisms. Murine double minute-2 (MDM2) is an oncoprotein that inhibits TP53 activity. A number of studies have examined the association of TP53 and MDM2 polymorphisms with the risk of common forms of cancer, but the findings remain inconclusive. The present study aimed to evaluate the impact of the 40‑bp insertion/deletion (I/D) polymorphism (rs3730485) in the MDM2 promoter region and the 16‑bp I/D polymorphism (rs17878362) in TP53 on the susceptibility of prostate cancer (PCa) in a sample of the Iranian population. This case‑control study included 103 patients with pathologically confirmed PCa and 142 patients with benign prostatic hyperplasia. The MDM2 40‑bp I/D and TP53 16‑bp I/D polymorphism was determined using polymerase chain reaction analysis. The results demonstrated that the MDM2 40‑bp I/D polymorphism increased the risk of PCa in a co‑dominant inheritance model [odds ratio (OR)=1.88; 95% confidence interval (CI)=1.11‑3.19; P=0.023, D/D vs. I/I], while this variant marginally increased the risk of PCa in a dominant model (OR=1.69; 95% CI=1.00‑2.83; P=0.051, I/D+D/D vs. I/I). No significant association was observed between the TP53 16-bp I/D polymorphism and PCa. In conclusion, the present study demonstrated that the 40‑bp I/D polymorphism in the MDM2 promoter increased the risk of PCa in an Iranian population. Further investigations with diverse ethnicities and larger sample sizes are required to verify these results.

Related Articles

Journal Cover

April-2017
Volume 13 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hashemi M, Amininia S, Ebrahimi M, Simforoosh N, Basiri A, Ziaee SA, Narouie B, Sotoudeh M, Mollakouchekian MJ, Rezghi Maleki E, Rezghi Maleki E, et al: Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. Oncol Lett 13: 2483-2489, 2017
APA
Hashemi, M., Amininia, S., Ebrahimi, M., Simforoosh, N., Basiri, A., Ziaee, S.A. ... Ghavami, S. (2017). Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. Oncology Letters, 13, 2483-2489. https://doi.org/10.3892/ol.2017.5739
MLA
Hashemi, M., Amininia, S., Ebrahimi, M., Simforoosh, N., Basiri, A., Ziaee, S. A., Narouie, B., Sotoudeh, M., Mollakouchekian, M. J., Rezghi Maleki, E., Hanafi‑Bojd, H., Rezaei, M., Bahari, G., Taheri, M., Ghavami, S."Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer". Oncology Letters 13.4 (2017): 2483-2489.
Chicago
Hashemi, M., Amininia, S., Ebrahimi, M., Simforoosh, N., Basiri, A., Ziaee, S. A., Narouie, B., Sotoudeh, M., Mollakouchekian, M. J., Rezghi Maleki, E., Hanafi‑Bojd, H., Rezaei, M., Bahari, G., Taheri, M., Ghavami, S."Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer". Oncology Letters 13, no. 4 (2017): 2483-2489. https://doi.org/10.3892/ol.2017.5739